MBSR,
does it really help with Reducing generalized anxiety disorder symptoms more than active stress education?
research showsMBSR has a signal of benefit for anxiety but is rated C. Hoge 2013 in the Journal of Clinical Psychiatry randomized 93 participants and analyzed 89 by modified intention to treat; the prespecified primary HAMA group-by-time effect failed, F(1,87)=1.38, P=.244, while positive CGI and BAI findings were secondary endpoints, invoking rule ①-ⓑ. Addressing a different question, Hoge 2023 in JAMA Psychiatry randomized 276 participants and met the primary eight-week CGI-S noninferiority endpoint versus escitalopram, but used a 208-treatment-completer per-protocol analysis. verdict 1505, which is B with 74 points, concerns a different intervention and indication.
ads claimMarketing can turn noninferiority to medication into claims of proven superiority over education or broad treatment of every anxiety disorder. The direct superiority primary endpoint failed.
Useful facts when choosing a product
- Standard MBSR usually includes weekly group classes, daily home practice, and an all-day retreat over eight weeks.
- Brief app meditation or generic mindfulness content is not the same intervention tested in these trials.
- Severe anxiety, suicidality, mania, psychosis, or major functional decline requires professional assessment rather than meditation alone.
What the research actually shows
Hoge 2013 in the Journal of Clinical Psychiatry randomized 93 adults with generalized anxiety disorder to MBSR or time- and attention-matched stress-management education and analyzed 89 by modified intention to treat. The prespecified primary HAMA group-by-time effect failed, F(1,87)=1.38, P=.244, while positive CGI and BAI findings were secondary endpoints. Addressing a different question, Hoge 2023 in JAMA Psychiatry randomized 276 adults with anxiety disorders to MBSR or escitalopram and met the primary eight-week CGI-S noninferiority endpoint in a per-protocol analysis of 208 treatment completers.
Why this is classified as C (42)
Superiority over active education failed and positive findings were secondary; the separate active-drug noninferiority success relied on 208 treatment completers in a per-protocol analysis. This places the verdict at C with 42 points, while substantive active-drug noninferiority evidence prevents D.
Counterpoint. MBSR can be considered through shared decision-making when a patient prefers structured nonpharmacologic care, but benefit is not guaranteed.
Rejudgment record. Cross-check applied — Applied rule ①-ⓑ to Hoge 2013 because its prespecified primary HAMA endpoint failed while positive CGI and BAI findings were secondary; treated Hoge 2023 as a different question whose active-drug noninferiority success was limited by a 208-completer per-protocol analysis, with substantive noninferiority evidence preventing D
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduction of HAMA anxiety symptoms versus active stress education | D | The prespecified primary group-by-time effect failed with P=.244. |
| Improvement in CGI and BAI anxiety outcomes | C | Some subjective secondary outcomes were positive, but they followed a failed primary endpoint. |
| Eight-week anxiety-symptom noninferiority to escitalopram | B | Noninferiority succeeded, but this was not superiority over placebo or education. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Hoge EA et al. 2013 | Randomized active-control trial | 89 | US NIH National Center for Complementary and Alternative Medicine grant K23AT4432; not manufacturer-led | Primary HAMA; secondary CGI and BAI | The prespecified primary HAMA group-by-time effect failed (F(1,87)=1.38, P=.244); positive CGI and BAI findings were secondary endpoints. | Key direct superiority evidence |
| Hoge EA et al. 2023 | Randomized active-drug noninferiority trial | 1 | Supported by the Patient-Centered Outcomes Research Institute and NYU Innovation Fund; not manufacturer-led | Noninferiority to escitalopram in eight-week CGI-S change | MBSR -1.35 and escitalopram -1.43; a -0.07 difference met the primary noninferiority endpoint. | Supportive active-control evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] MBSR x improvement of generalized anxiety disorder symptoms — Evidence Grade C·42. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/mood/mbsr-generalized-anxiety-active-control/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.